Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

TI Fluid FY profits weighed down by restructuring costs, exceptional charge

(Sharecast News) - Automotive fluid storage business TI Fluid Systems said on Tuesday that statutory operating profits had sunk in FY24 due to higher restructuring costs and a non-cash write-down of intangible assets. TI Fluid Systems said statutory operating profits were down 32.4% at €132.4m in FY24, while revenues slipped 4.4% to €3.36bn. On an adjusted basis, underlying earnings ticked up 0.5% to €260.8m as adjusted EBIT margins expanded 40 basis points to 7.8%.

The London-listed group stated a €40.6m exceptional charge related to the closure of its manufacturing facility in Ligonier, as well as the associated exit of the powertrain business, and a jump in restructuring costs from €13.4m to €37.4m were mostly to blame for the drop in FY profits.

Bookings remained strong at €2.7bn, down from €3.0bn, as did the group's balance sheet, with a net leverage position of 1.6X adjusted EBITDA at year-end.

Chief executive Hans Dieltjens said: "Our financial performance was driven by relentless commercial execution and the benefits of our intensified productivity and efficiency measures. We also continued to successfully execute our strategic priorities by further investing in our EV growth opportunities and maximising our conventional portfolio.

"Together we have accelerated our transition to electrification and ensured TI is well-positioned to continue to deliver on its vision and create value for all stakeholders as part of an enlarged group."

As of 0920 GMT, TI Fluid shares were down 0.051% at 196.50p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.